EBS News and Press, Emergent Biosolutions Inc. From 04/29/22

Emergent BioSolutions (NYSE:EBS) trades lower during the day's trade after Cowen lowered price target to $30 from $40 while maintaining its Market Perform rating on the shares. Analyst Boris Peaker noted the anthrax vaccine and Narcan revenues were ahead of guidance but Narcan is likely to sh...

Shares of Emergent BioSolutions (NYSE: EBS) were sinking 7.7% as of noon ET on Friday. The decline came after the company announced its first-quarter results following the market close on Thursday. Emergent BioSolutions reported Q1 revenue of $308 million, down 10% year over yea...

Emergent BioSolutions Inc. (EBS) Q1 2022 Results Conference Call April 28, 2022 05:00 PM ET Company Participants Bob Burrows - VP, IR Bob Kramer - President and CEO Rich Lindahl - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald Lisa Springer - Singular Research Presentatio...

Emergent Biosolutions (NYSE:EBS) stock fell ~8% after the company on Thursday said it was temporarily suspending total revenue and Contract Development and Manufacturing (CDMO) guidance pending further clarity on Johnson & Johnson's (J&J) COVID-19 vaccine requireme...

Emergent Biosolutions press release (NYSE:EBS): Q1 Non-GAAP EPS of $0.18 beats by $0.11. Revenue of $307.5M (-10.3% Y/Y) beats by $24.96M. For further details see: Emergent Biosolutions Non-GAAP EPS of $0.18 beats by $0.11, revenue of $307.5M beats by $24.96M

Reports Q1 2022 total revenues of $308M, in line with guidance, and Adjusted EBITDA of $36M Temporarily suspends CDMO guidance pending further clarity on COVID-19 vaccine requirements GAITHERSBURG, Md., April 28, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) to...

Emergent Biosolutions (EBS) is scheduled to announce Q1 earnings results on Thursday, April 28th, after market close. The consensus EPS Estimate is $0.12 (-92.2% Y/Y) and the consensus Revenue Estimate is $284.12M (-17.2% Y/Y). Over the last 2 years, EBS has beaten EPS estimates 75% of the ti...

Some of these stocks present long opportunities as they pull back. Others have held support and already begun to bounce. This was a video from Monday – just one of four videos we provide subscribers each week. For further details see: 8 Wave Setups To Watch (Video...

GAITHERSBURG, Md., April 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2022, recent business developments, revenue guidance for th...

Emergent BioSolutions (NYSE:EBS) appointed Zsolt Harsanyi, independent director, as chairman of the board. EBS decided to eliminate the role of executive chairman in favor of an independent, non-executive chairman and will no longer require the role of lead independent director. Ronald R...